Physician profile
Jorge E Martinez
NPI 1114984895
$1,024.67
in general payments reported to CMS, 2019-2025
10 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.26 · 2020: $59.59 · 2021: $165 · 2022: $255 · 2023: $35.87 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $360.29 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals Lp | $134.71 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.77 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.88 | 2021-2023 | |
| Bayer Puerto Rico INC. | $96.46 | 2025 | Kerendia |
| Amgen INC. | $66.99 | 2021-2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.10 | 2020-2022 | |
| Genentech USA, INC. | $33.23 | 2021 | |
| Lilly USA, LLC | $21.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.37 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.